U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Primary Vitreoretinal Diffuse Large B-Cell Lymphoma

MedGen UID:
1683653
•Concept ID:
C4763394
•
Neoplastic Process
Synonym: Refractory PVRL DLBCL

Definition

Primary vitreoretinal diffuse large B-cell lymphoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Primary Vitreoretinal Diffuse Large B-Cell Lymphoma

Recent clinical studies

Etiology

Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.
Mumtaz AA, Fischer A, Lutfi F, Matsumoto LR, Atanackovic D, Kolanci ET, Hankey KG, Hardy NM, Yared JA, Kocoglu MH, Rapoport AP, Dahiya S, Li AS, Sunshine SB
Br J Ophthalmol 2023 Jul;107(7):901-905. Epub 2022 Feb 10 doi: 10.1136/bjophthalmol-2021-320814. PMID: 35144919
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens.
Albadri ST, Pulido JS, Macon WR, Garcia JJ, Salomao DR
Retina 2020 Feb;40(2):391-398. doi: 10.1097/IAE.0000000000002676. PMID: 31972811
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Moluçon-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonnière M, El Yamani A, Ghesquières H, Hoang-Xuan K
Eur J Cancer 2019 Aug;117:121-130. Epub 2019 Jul 3 doi: 10.1016/j.ejca.2019.05.024. PMID: 31279304
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C
Ann Oncol 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. PMID: 30698644

Diagnosis

How we treat primary central nervous system lymphoma.
Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM
ESMO Open 2021 Aug;6(4):100213. Epub 2021 Jul 13 doi: 10.1016/j.esmoop.2021.100213. PMID: 34271311Free PMC Article
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens.
Albadri ST, Pulido JS, Macon WR, Garcia JJ, Salomao DR
Retina 2020 Feb;40(2):391-398. doi: 10.1097/IAE.0000000000002676. PMID: 31972811

Therapy

Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.
Mumtaz AA, Fischer A, Lutfi F, Matsumoto LR, Atanackovic D, Kolanci ET, Hankey KG, Hardy NM, Yared JA, Kocoglu MH, Rapoport AP, Dahiya S, Li AS, Sunshine SB
Br J Ophthalmol 2023 Jul;107(7):901-905. Epub 2022 Feb 10 doi: 10.1136/bjophthalmol-2021-320814. PMID: 35144919
How we treat primary central nervous system lymphoma.
Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM
ESMO Open 2021 Aug;6(4):100213. Epub 2021 Jul 13 doi: 10.1016/j.esmoop.2021.100213. PMID: 34271311Free PMC Article
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Moluçon-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonnière M, El Yamani A, Ghesquières H, Hoang-Xuan K
Eur J Cancer 2019 Aug;117:121-130. Epub 2019 Jul 3 doi: 10.1016/j.ejca.2019.05.024. PMID: 31279304
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C
Ann Oncol 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. PMID: 30698644

Prognosis

HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens.
Albadri ST, Pulido JS, Macon WR, Garcia JJ, Salomao DR
Retina 2020 Feb;40(2):391-398. doi: 10.1097/IAE.0000000000002676. PMID: 31972811
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Moluçon-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonnière M, El Yamani A, Ghesquières H, Hoang-Xuan K
Eur J Cancer 2019 Aug;117:121-130. Epub 2019 Jul 3 doi: 10.1016/j.ejca.2019.05.024. PMID: 31279304
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C
Ann Oncol 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. PMID: 30698644

Clinical prediction guides

HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens.
Albadri ST, Pulido JS, Macon WR, Garcia JJ, Salomao DR
Retina 2020 Feb;40(2):391-398. doi: 10.1097/IAE.0000000000002676. PMID: 31972811
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C
Ann Oncol 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. PMID: 30698644

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...